PCC

One of the challenges faced by the psychedelics industry is that trauma and mental illness are tied to income, yet off-label ketamine treatment is not yet covered by insurance, Klee Irwin, founder, CEO, & chairman of Irwin Naturals (OTC: IWINF) told the inaugural...

Larry Schnurmacher, one of Phyto Partners’ cofounders has long experience in emerging markets. His venture capital fund has greatly supported 35 cannabis companies since 2015, and, with Pytho Psyche, he began investing in psychedelics-oriented companies. More investment in this...

For many private companies, the goal is clear: to go public. For others, the goal is an acquisition. Either way, private companies offer attractive potential for investors, especially in emerging markets. And the psychedelic space is just that.  “I think we will see money leave the...

There were more than 30 different companies in the psychedelic space present at the inaugural Benzinga Psychedelics Capital Conference on Tuesday. But, Enveric is one of the only ones that offer investors exposure to both the psychedelic and cannabis space. Enveric Biosciences Inc (NASDAQ...

Cory Jones of Healing Maps told Benzinga’s Javier Hasse at the inaugural Benzinga Psychedelics Capital Conference on Tuesday that research underway at such institutions as Johns Hopkins University and London’s Imperial College is "changing people’s minds...

While “Shark Tank” judge Kevin O’Leary views legal psychedelics as a once-in-a-lifetime investment opportunity, his take on cannabis is 180 degrees away. “There isn’t a dime of institutional money here, at the sovereign level,” O’Leary told Benzinga founder...

The market opportunity for legal psychedelics is in the hundreds of billions of dollars, “Shark Tank” judge Kevin O’Leary told the inaugural Benzinga Psychedelics Capital Conference on Tuesday. Investors never get the opportunity to position themselves in a brand new sector,...